Literature DB >> 21593733

Multilocus genetic profile for dopamine signaling predicts ventral striatum reactivity.

Yuliya S Nikolova1, Robert E Ferrell, Stephen B Manuck, Ahmad R Hariri.   

Abstract

Research integrating neuroimaging and molecular genetics has yielded important insights into how variability in brain chemistry predicts individual differences in brain function, behavior and related risk for psychopathology. However, existing studies have been limited by their focus on the independent effects of single polymorphisms with modest impact on brain chemistry. Here, we explored the effects of five functional polymorphisms affecting dopamine (DA) signaling on reward-related ventral striatum (VS) reactivity, measured with BOLD fMRI, in a sample of 69 Caucasians. We also compiled individual multilocus genetic profile scores reflecting the additive effects of alleles conferring relatively increased DA signaling across the five polymorphic loci: DAT1 9-repeat, DRD4 7-repeat, DRD2 -141C Del, DRD2 Taq1A C (A2), and COMT (158)Met. These multilocus DA profile scores accounted for 10.9% of the inter-individual variability in reward-related VS reactivity. In contrast, none of the individual polymorphisms accounted for significant variability. Our results show that biologically informed multilocus genetic profiles have unique promise as indices of variability in brain chemistry that may yield advances in mapping individual differences in behaviorally relevant brain function. In turn, such genetic profiles may fuel gene-environment interactions research establishing trajectories of risk for psychopathology.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21593733      PMCID: PMC3154113          DOI: 10.1038/npp.2011.82

Source DB:  PubMed          Journal:  Neuropsychopharmacology        ISSN: 0893-133X            Impact factor:   7.853


  55 in total

1.  Antipsychotic-induced tardive dyskinesia and polymorphic variations in COMT, DRD2, CYP1A2 and MnSOD genes: a meta-analysis of pharmacogenetic interactions.

Authors:  P R Bakker; P N van Harten; J van Os
Journal:  Mol Psychiatry       Date:  2008-01-08       Impact factor: 15.992

2.  Evidence of biologic epistasis between BDNF and SLC6A4 and implications for depression.

Authors:  L Pezawas; A Meyer-Lindenberg; A L Goldman; B A Verchinski; G Chen; B S Kolachana; M F Egan; V S Mattay; A R Hariri; D R Weinberger
Journal:  Mol Psychiatry       Date:  2008-03-18       Impact factor: 15.992

3.  Variation in TREK1 gene linked to depression-resistant phenotype is associated with potentiated neural responses to rewards in humans.

Authors:  Daniel G Dillon; Ryan Bogdan; Jesen Fagerness; Avram J Holmes; Roy H Perlis; Diego A Pizzagalli
Journal:  Hum Brain Mapp       Date:  2010-02       Impact factor: 5.038

4.  Taq1A polymorphism in the dopamine D2 receptor gene as a predictor of clinical response to aripiprazole.

Authors:  Jun Soo Kwon; Euitae Kim; Do-Hyung Kang; Jung Seok Choi; Kyung-Sang Yu; In-Jin Jang; Sang-Goo Shin
Journal:  Eur Neuropsychopharmacol       Date:  2008-09-10       Impact factor: 4.600

5.  Relation between obesity and blunted striatal response to food is moderated by TaqIA A1 allele.

Authors:  E Stice; S Spoor; C Bohon; D M Small
Journal:  Science       Date:  2008-10-17       Impact factor: 47.728

6.  Catechol-O-methyltransferase val158met genotype influences neural processing of reward anticipation.

Authors:  Katharina Schmack; Florian Schlagenhauf; Philipp Sterzer; Jana Wrase; Anne Beck; Theresa Dembler; Peter Kalus; Imke Puls; Thomas Sander; Andreas Heinz; Jürgen Gallinat
Journal:  Neuroimage       Date:  2008-06-25       Impact factor: 6.556

7.  Dopamine in amygdala gates limbic processing of aversive stimuli in humans.

Authors:  Thorsten Kienast; Ahmad R Hariri; Florian Schlagenhauf; Jana Wrase; Philipp Sterzer; Hans Georg Buchholz; Michael N Smolka; Gerhard Gründer; Paul Cumming; Yoshitaka Kumakura; Peter Bartenstein; Raymond J Dolan; Andreas Heinz
Journal:  Nat Neurosci       Date:  2008-11-02       Impact factor: 24.884

8.  Mesolimbic dopamine reward system hypersensitivity in individuals with psychopathic traits.

Authors:  Joshua W Buckholtz; Michael T Treadway; Ronald L Cowan; Neil D Woodward; Stephen D Benning; Rui Li; M Sib Ansari; Ronald M Baldwin; Ashley N Schwartzman; Evan S Shelby; Clarence E Smith; David Cole; Robert M Kessler; David H Zald
Journal:  Nat Neurosci       Date:  2010-03-14       Impact factor: 24.884

9.  Dissociable cost and benefit encoding of future rewards by mesolimbic dopamine.

Authors:  Jerylin O Gan; Mark E Walton; Paul E M Phillips
Journal:  Nat Neurosci       Date:  2009-11-10       Impact factor: 24.884

10.  Genetic correlates of brain aging on MRI and cognitive test measures: a genome-wide association and linkage analysis in the Framingham Study.

Authors:  Sudha Seshadri; Anita L DeStefano; Rhoda Au; Joseph M Massaro; Alexa S Beiser; Margaret Kelly-Hayes; Carlos S Kase; Ralph B D'Agostino; Charles Decarli; Larry D Atwood; Philip A Wolf
Journal:  BMC Med Genet       Date:  2007-09-19       Impact factor: 2.103

View more
  97 in total

1.  Mineralocorticoid receptor Iso/Val (rs5522) genotype moderates the association between previous childhood emotional neglect and amygdala reactivity.

Authors:  Ryan Bogdan; Douglas E Williamson; Ahmad R Hariri
Journal:  Am J Psychiatry       Date:  2012-05       Impact factor: 18.112

2.  Predicting white matter integrity from multiple common genetic variants.

Authors:  Omid Kohannim; Neda Jahanshad; Meredith N Braskie; Jason L Stein; Ming-Chang Chiang; April H Reese; Derrek P Hibar; Arthur W Toga; Katie L McMahon; Greig I de Zubicaray; Sarah E Medland; Grant W Montgomery; Nicholas G Martin; Margaret J Wright; Paul M Thompson
Journal:  Neuropsychopharmacology       Date:  2012-04-18       Impact factor: 7.853

Review 3.  Understanding risk for psychopathology through imaging gene-environment interactions.

Authors:  Luke W Hyde; Ryan Bogdan; Ahmad R Hariri
Journal:  Trends Cogn Sci       Date:  2011-08-10       Impact factor: 20.229

4.  A neurogenetics approach to defining differential susceptibility to institutional care.

Authors:  Zoe H Brett; Margaret Sheridan; Kate Humphreys; Anna Smyke; Mary Margaret Gleason; Nathan Fox; Charles Zeanah; Charles Nelson; Stacy Drury
Journal:  Int J Behav Dev       Date:  2015-03

5.  Father Loss and Child Telomere Length.

Authors:  Colter Mitchell; Sara McLanahan; Lisa Schneper; Irv Garfinkel; Jeanne Brooks-Gunn; Daniel Notterman
Journal:  Pediatrics       Date:  2017-07-18       Impact factor: 7.124

6.  The conditioning of intervention effects on early adolescent alcohol use by maternal involvement and dopamine receptor D4 (DRD4) and serotonin transporter linked polymorphic region (5-HTTLPR) genetic variants.

Authors:  H Harrington Cleveland; Gabriel L Schlomer; David J Vandenbergh; Mark Feinberg; Mark Greenberg; Richard Spoth; Cleve Redmond; Mark D Shriver; Arslan A Zaidi; Kerry L Hair
Journal:  Dev Psychopathol       Date:  2015-02

7.  Family structure instability, genetic sensitivity, and child well-being.

Authors:  Colter Mitchell; Jeanne Brooks-Gunn; Irwin Garfinkel; Sara McLanahar; Daniel Notterman; John Hobcraft
Journal:  AJS       Date:  2015-01

8.  Interacting effects of naltrexone and OPRM1 and DAT1 variation on the neural response to alcohol cues.

Authors:  Joseph P Schacht; Raymond F Anton; Konstantin E Voronin; Patrick K Randall; Xingbao Li; Scott Henderson; Hugh Myrick
Journal:  Neuropsychopharmacology       Date:  2012-10-03       Impact factor: 7.853

9.  Effects of a GWAS-Supported Schizophrenia Variant in the DRD2 Locus on Disease Risk, Anhedonia, and Prefrontal Cortical Thickness.

Authors:  Margarita V Alfimova; Nikolay V Kondratyev; Alexander S Tomyshev; Irina S Lebedeva; Tatyana V Lezheiko; Vasiliy G Kaleda; Lilia I Abramova; Vera E Golimbet
Journal:  J Mol Neurosci       Date:  2019-05-03       Impact factor: 3.444

10.  Genetic Heterogeneity in Adolescents' Depressive Symptoms in Response to Victimization.

Authors:  Nisha C Gottfredson; Vangie A Foshee; Susan T Ennett; Brett Haberstick; Andrew Smolen
Journal:  J Clin Child Adolesc Psychol       Date:  2014-05-12
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.